Erenumab-Aooe — Active Pharmaceutical Ingredient

Erenumab-Aooe is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: INJECTABLE. Routes: INJECTION.

This content is for informational purposes only. Always consult a healthcare professional.

Erenumab-Aooe (1 brand name, 1 dosage form, 1 route)

Available dosage forms: INJECTABLE.

Routes of administration: INJECTION.

Brand Names

  • AIMOVIG

Indications and Usage

AIMOVIG is indicated for the preventive treatment of migraine in adults.

Contraindications

AIMOVIG is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.1)].

Adverse Reactions

The following serious adverse reactions are described below and elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Constipation with Serious Complications [see Warnings and Precautions (5.2)] Hypertension [see Warnings and Precautions (5.3)] Raynaud’s Phenomenon [see Warnings and Precautions (5.4)]

Mechanism of Action

Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.